pmjТихоокеанский медицинский журналPacific Medical Journal1609-1175TGMU10.34215/1609-1175-2021-2-14-18pmj-2190Research ArticleОБЗОРЫREVIEWSЭволюция методов радиосенсибилизации в лучевой терапии злокачественных новообразованийEvolution of radio sensibilization methods in radiotherapy of malignant tumorshttps://orcid.org/0000-0002-1648-2556ПлотниковаО. С.PlotnikovaO. S.

 аспирант, врач

690002, г. Владивосток, пр-т Острякова

MD; PhD student

2 Ostryakova Ave., Vladivostok, 690002, Russian Federation

radiolog2906@gmail.comhttps://orcid.org/0000-0003-0808-5283АпанасевичВ. И.ApanasevichV. I.

д-р мед. наук, профессор Института хирургии

690002, г. Владивосток, пр-т Острякова, 2

MD, PhD, professor, Institute of Surgery

2 Ostryakova Ave., Vladivostok, 690002, Russian Federation

oncolog222@gmail.comКнязенкоП. А.KnyazenkoP. A.

врач

690078, г. Владивосток, ул. Садовая, 22

MD

22 Sadovaya St., Vladivostok, 690078, Russian Federation

ШестаковаА. А.ShestakovaA. A.

студентка 3 курса лечебного факультета

690002, г. Владивосток, пр-т Острякова, 2

student,

92 Ostryakova Ave., Vladivostok, 690002, Russian Federation

КарлинаВ. П.KarlinaV. P.

студентка 3 курса лечебного факультета

690002, г. Владивосток, пр-т Острякова, 2

student

92 Ostryakova Ave., Vladivostok, 690002, Russian Federation

КоренковП. Г.KorenkovP. G.

студент 3 курса лечебного факультета

690002, г. Владивосток, пр-т Острякова, 2

student

92 Ostryakova Ave., Vladivostok, 690002, Russian Federation

Тихоокеанский государственный медицинский университет; Приморский краевой онкологический диспансерРоссияPacific State Medical University; Primorsky Regional Oncological DispensaryRussian FederationВладивостокская клиническая больница № 1РоссияVladivostok Clinical Hospital No. 1Russian FederationТихоокеанский государственный медицинский университетРоссияPacific State Medical UniversityRussian Federation202120062021021418Copyright © Плотникова О.С., Апанасевич В.И., Князенко П.А., Шестакова А.А., Карлина В.П., Коренков П.Г., 20212021Плотникова О.С., Апанасевич В.И., Князенко П.А., Шестакова А.А., Карлина В.П., Коренков П.Г.Plotnikova O.S., Apanasevich V.I., Knyazenko P.A., Shestakova A.A., Karlina V.P., Korenkov P.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tmj-vgmu.ru/jour/article/view/2190

 Представлен обзор публикаций, посвященных применению радиосенсибилизаторов при лучевой терапии опухолей. В настоящее время в онкологии широко используются такие  радиомодификационные агенты, как платина, фторурацил, золото, гадолиний, йод и др. Рассмотрены основные методы  применения и способы введения соединений тяжелых металлов и оценено их влияние на показатели острой и  хронической токсичности у пациентов, страдающих  злокачественными новообразованиями. 

 Publications survey devoted to the usage of radio sensitizers for radiation therapy of the tumors is demonstrated. Currently such radiomodification agents as platinum, fluorouracil, gold, gadolinium, iodine, etc. are widely used in oncology. General application methods and ways of introducing heavy metals compounds are highlighted. Their influence on the indexes of the acute and  chronic toxicity among patients suffering malignancies is estimated. 

радиосенсибилизациярадиомодификациялучевая терапияонкологияradiosensitizationradiomodificationradiation therapyoncologyReferencesУльяненко С.Е., Политюкова Н.А. Радиомодифицирующий эффект гипергликемии, зависимость от дозы глюкозы и объема опухоли. Медицинская радиология. 1991;1:21–3.Ulyanenko SE, Polityukova NA. Radimodifying effect of hyperglycemia, glucose and tumor dose dependence. Medical Radiology. 1991;1:21–3 (In Russ).Муфазалов Ф.Ф., Набуиллина М.К., Лоскутов Л.А. Использование метронидазола в лучевой терапии рака мочевого пузыря. Медицинская радиология. 1992;3–4:21–3.Mufazalov FF, Nabuillina MK, Loskutov LA. The use of metronidazole in radiation therapy for bladder cancer. Medical Radiology. 1992; 3–4:21–3 (In Russ).Bleehen MN. Lung cuncer – still a long road ahead. Brit J Cancer. 1990;61:493–4.Bleehen MN. Lung cuncer – still a long road ahead. Brit J Cancer. 1990;61:493–4.Cole D.J., Jones A.C. The treatment of locally advanced carcinoma of the cervix with radiation, 5-fluorouracil and mitomycin C. Brit J Cancer. 1993;66:52.Cole D.J., Jones A.C. The treatment of locally advanced carcinoma of the cervix with radiation, 5-fluorouracil and mitomycin C. Brit J Cancer. 1993;66:52.Micksche M. Interferon-ein neues therapeutisches prinzip. Wien Med Wochens Chr. 1993;143(16–17):408–12.Micksche M. Interferon-ein neues therapeutisches prinzip. Wien Med Wochens Chr. 1993;143(16–17):408–12.Максимов С.Я., Гусейнов К.Д. Комбинированное лечение рака шейки матки. Практическая онкология. 2002;3(3):200–10.Maksimov SYa, Guseinov KD. Combined treatment for cervical cancer. Practical Oncology. 2002;3(3):200–10 (In Russ).Gastrointestinal Tumor Study Group. Prolongation of the diseasefree interval in surgically treated rectal carcinoma. New Engl J Med. 1985;312:1465–72.Gastrointestinal Tumor Study Group. Prolongation of the diseasefree interval in surgically treated rectal carcinoma. New Engl J Med. 1985;312:1465–72.Krook JE, Moeretel CG, Gunderson L.L., Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. New Engl J Med. 1991;324:709–15.Krook JE, Moeretel CG, Gunderson L.L., Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. New Engl J Med. 1991;324:709–15.National Institutes of Health Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–50.National Institutes of Health Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–50.Дворниченко В.В., Афанасьев С.Г., Шелехов А.В., Москвина Н.А. Лучевая терапия в комбинированном лечении рака прямой кишки: обзор литературы. Сибирский онкологический журнал. 2009;1:72–7.Dvornichenko VV, Afanasyev SG, Shelekhov AV, Moskvina NA. Radiation therapy in combination therapy for rectal cancer: A literature review. Siberian Journal of Oncology. 2009;1:72–7 (In Russ).Основы клинической радиобиологии. Под ред. М.С. Джойнера, О. Дж. ван дер Когеля / пер. с англ. М.: Лаборатория знаний, 2014.Joiner M, van der Kogel A, eds. Basic Clinical Radiobiology. Moscow: Laboratoriya Znaniy; 2014 (In Russ).Wolmark N., Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000;92(5):388–96.Wolmark N., Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000;92(5):388–96.Allegra CJ, Yothers G, O’Connell MJ, Beart RW, Wozniak TF, Pitot HC, et al. Neoadjuvant 5-FU or Capecitabine plus radiation with or without Oxaliplatin in rectal cancer patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst. 2015;107(11):djv248. doi: 10.1093/jnci/djv248.Allegra CJ, Yothers G, O’Connell MJ, Beart RW, Wozniak TF, Pitot HC, et al. Neoadjuvant 5-FU or Capecitabine plus radiation with or without Oxaliplatin in rectal cancer patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst. 2015;107(11):djv248. doi: 10.1093/jnci/djv248.Louafi S, Mansourbakht T, Bonyhay L, Taïeb J. Oxaliplatine en oncologie digestive en dehors du cancer colorectal [Oxaliplatin in gastro-intestinal tract cancer except colorectal cancer]. Bull Cancer. 2006;93(Suppl 1):S23–33.Louafi S, Mansourbakht T, Bonyhay L, Taïeb J. Oxaliplatine en oncologie digestive en dehors du cancer colorectal [Oxaliplatin in gastro-intestinal tract cancer except colorectal cancer]. Bull Cancer. 2006;93(Suppl 1):S23–33.Hofheinz RD, Arnold D, Fokas E, Kaufmann M, Hothorn T, Folprecht G, et al. German Rectal Cancer Study Group. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: A post hoc analysis of the CAO/ARO/AIO-04 phase III trial. Ann Oncol. 2018;29(8):1793–9.Hofheinz RD, Arnold D, Fokas E, Kaufmann M, Hothorn T, Folprecht G, et al. German Rectal Cancer Study Group. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: A post hoc analysis of the CAO/ARO/AIO-04 phase III trial. Ann Oncol. 2018;29(8):1793–9.Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): Final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89.Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): Final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89.van Dijk TH, Tamas K, Beukema JC, Beets GL, Gelderblom AJ, de Jong KP, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol. 2013;24(7):1762–9.van Dijk TH, Tamas K, Beukema JC, Beets GL, Gelderblom AJ, de Jong KP, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol. 2013;24(7):1762–9.Punushapai U, Yuenyao P, Chumworathayi B, Luanratanakorn S, Udomthavornsuk B. Weekly cisplatin 20 mg/m2 in patients with carcinoma of cervix receiving pelvic radiotherapy at Srinagarind Hospital: A randomized controlled trial. Asian Pac J Cancer Prev. 2010;11(1):201–7.Punushapai U, Yuenyao P, Chumworathayi B, Luanratanakorn S, Udomthavornsuk B. Weekly cisplatin 20 mg/m2 in patients with carcinoma of cervix receiving pelvic radiotherapy at Srinagarind Hospital: A randomized controlled trial. Asian Pac J Cancer Prev. 2010;11(1):201–7.Spinelli A, Girelli M, Arosio D, Polito L, Podini P, Martino G, et al. Intracisternal delivery of PEG-coated gold nanoparticles results in high brain penetrance and long- lasting stability. J Nanobiotechnology. 2019;17(1):49. doi: 10.1186/s12951-019-0481-3Spinelli A, Girelli M, Arosio D, Polito L, Podini P, Martino G, et al. Intracisternal delivery of PEG-coated gold nanoparticles results in high brain penetrance and long- lasting stability. J Nanobiotechnology. 2019;17(1):49. doi: 10.1186/s12951-019-0481-3Hwang C, Kim JM, Kim J. Influence of concentration, nanoparticle size, beam energy, and material on dose enhancement in radiation therapy. J Radiat Res. 2017;58(4):405–11.Hwang C, Kim JM, Kim J. Influence of concentration, nanoparticle size, beam energy, and material on dose enhancement in radiation therapy. J Radiat Res. 2017;58(4):405–11.

The authors declare that there are no conflicts of interest present.